FDA Clearance Tracker · P160031
ASPIRE CRISTALLE DIGITAL BREAST TOMOSYNTHESIS OPTION
Last checked: Nov 19, 2026Latest source record: Jan 10, 2017 (this decision)Source: openFDAMethods & limitations
Decided
Jan 10, 2017
Approved
Time to decision
162 days
Received Aug 1, 2016. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P160031
- Device name
- ASPIRE CRISTALLE DIGITAL BREAST TOMOSYNTHESIS OPTION
- Applicant
- Fujifilm Medical Systems U.S.A, Inc.
- Applicant location
- Stamford, CT
- Received
- Aug 1, 2016
- Decided
- Jan 10, 2017
- Decision
- Approved
- Supplements
- 4 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Digital breast tomosynthesis (OTE)
- Device class
- Class III
- Specialty
- Radiology & Imaging
FDA's approval statement
As written in FDA's record.
Approval for the Aspire Cristalle Digital Breast Tomosynthesis Option. The Fujifilm ASPIRE Cristalle with Digital Breast Tomosynthesis (DBT) Option acquires and generates FFDM and DBT images, and is intended for use in the screening and diagnosis of breast cancer. A screening examination may consist of sets of CC and MLO images acquired in: 1) the FFDM mode only, or 2) an FFDM image set and a DBT image set acquired in the ST (standard) mode. The FFDM image set and the DBT image set must be acquired with N-mode dose setting, and may be acquired in one compression (Tomo Set mode) or separate compressions (FFDM and DBT modes).
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code OTE. The earliest in FDA's data is P080003, decided Feb 11, 2011.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Fujifilm Medical Systems U.S.A, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K171291 · Decided Jan 19, 2018 · 262 days after receipt
Device type: Bronchoscope (Flexible Or Rigid) (EOQ) · Otolaryngology (ENT)
K171207 · Decided Jan 11, 2018 · 261 days after receipt
Device type: Endoscopic Ultrasound System, Gastroenterology-Urology (ODG) · GI, Urology & Nephrology
- ASPIRE Cristalle510(k)
K173132 · Decided Oct 27, 2017 · 28 days after receipt
Device type: Full Field Digital, System, X-Ray, Mammographic (MUE) · Radiology & Imaging
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.